Invitrogen Sued Over Cell Technology
Celsis IVT recently reached a settlement with XenoTech in a patent infringement suit involving the same patent. The company describes the technology as one that combines hepatocytes from multiple donors to create large lots with targeted activity levels for use in ADME-Tox assays.
Baltimore, MD 6/30/10—Celsis In Vitro (Celsis IVT) a provider of specialized in vitro products, has filed suit against Invitrogen, a Life Technologies company, in US District Court in the Northern District of Illinois. The complaint alleges that processes and methods performed by Invitrogen’s CellzDirect subsidiary infringe Celsis IVT’s US Patent No. 7,604,929 (Novel Cellular Compositions and Methods for Their Preparation). The Patent relates to processes and methods for producing cryopreserved hepatocytes that are used to create Celsis IVT’s LiverPool products for drug discovery. Celsis IVT seeks a preliminary injunction as well as damages.
